Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Asset Writedowns and Impairment (2016 - 2025)

China Pharma Holdings' Asset Writedowns and Impairment history spans 11 years, with the latest figure at -$27029.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 94.1% year-over-year to -$27029.0; the TTM value through Dec 2025 reached $213684.0, up 147.12%, while the annual FY2025 figure was -$1018.0, 117.85% down from the prior year.
  • Asset Writedowns and Impairment reached -$27029.0 in Q4 2025 per CPHI's latest filing, down from $25302.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $213379.0 in Q1 2025 to a low of -$458282.0 in Q4 2024.
  • Average Asset Writedowns and Impairment over 5 years is -$26725.9, with a median of -$3212.0 recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 2924.19% in 2024, then surged 10428.12% in 2025.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at -$250622.0 in 2021, then surged by 95.96% to -$10136.0 in 2022, then surged by 260.09% to $16227.0 in 2023, then crashed by 2924.19% to -$458282.0 in 2024, then soared by 94.1% to -$27029.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Asset Writedowns and Impairment are -$27029.0 (Q4 2025), $25302.0 (Q3 2025), and $2032.0 (Q2 2025).